Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
The Phase I study could potentially result in RP-A501 becoming the first gene therapy for monogenic heart failure.
Robert Califf became the new commissioner of the U.S. Food & Drug Administration and emphasized the use of real-world evidence (RWE) in Agency decisions.
With all of this innovation coming down the pike, Gallant shared that Daiichi Sankyo is currently in growth mode, particularly when it comes to oncology.
Several cases of Japanese encephalitis have been confirmed in Australia and may have spread from pigs to humans, although it can also spread from horses.
The biopharma industry ended February and began March with plenty of clinical trial news. BioSpace shares the highlights.
Although at-home testing for COVID-19 has been dismal, the revolution in at-home testing has inspired personal tests for several other illnesses.
As COVID-19 cases fall in the wake of the latest surge from the Omicron variant, the question on the minds of many is, what comes next for these Pfizer and Moderna?
The European Commission has provided an update that it remains unconvinced by the merger, which spells bad news for Illumina.
The FDA turned down Ocugen’s Emergency Use Authorization request for Covaxin in children 2 to 18, which the company is co-developing with India’s Bharat Biotech.
A life science degree can provide various academic and professional opportunities to you. Here’s an overview of what you can do with a life science degree.
Atlas Venture raised $450 million at the close of its thirteenth fundraising activity to support efforts to create and invest in new biotech firms that address many unmet patient needs.
A study in monkeys found the virus infects the male genital tissues. For that and more COVID-19 news, continue reading.
PRESS RELEASES
New START site to be established in collaboration with Baptist Health Herbert Wertheim Cancer Institute will bring novel oncology therapies closer to patients across South Florida
• Augurex’s SPINEstat® (Anti-14-3-3eta Multiplex for axial spondyloarthritis) test has been selected as a finalist in the ADLM 2026 Disruptive Technology Award, one of laboratory medicine’s most competitive recognition programs. • Augurex will present at ADLM 2026 on July 27 in Anaheim, CA, with a dedicated finalist kiosk on the Expo Floor July 28–30. • The recognition underscores Augurex’s leadership in developing biomarker-driven diagnostics that address critical unmet needs across autoimmune and inflammatory diseases.
